The phase two trial involves the use of Bionomics' BNC105 in combination with Bristol Myers Squibb’s PBS-listed immunotherapy OPDIVO (nivolumab) in patients with metastatic colorectal cancer. …
Bionomics-BMS combination completes trial treatment phase
January 22, 2021 Australian BiotechBioPharmaLatest News
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 12 December
December 12, 2025 - - Podcast -
Medicines Australia gains a new voice with Vertex joining the association
December 11, 2025 - - Latest News -
BMS marks 70 years in Australia with renewed commitment to innovation and access
December 11, 2025 - - Latest News -
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - - Latest News -
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech